Flow cytometry in node-positive breast cancer: Cancer and leukemia group B protocol 8869-Reference-Cited by-同舟云学术

Flow cytometry in node-positive breast cancer: Cancer and leukemia group B protocol 8869

Published:1995-12-15 Issue:4 Volume:22 Page:297-306
ISSN:0196-4763
Container-title:Cytometry
language:en
Short-container-title:Cytometry

Author:

Kute Timothy E.,Quadri Yasmeen,Muss Hyman,Zbieranski Nora,Cirrincione Constance,Berry Donald A.,Barcos Maurice,Liu Edison,Thor Ann P.,Koerner Frederick,Henderson I. Craig

Publisher

Wiley

Subject

Cell Biology,Endocrinology,Hematology,Biophysics,Pathology and Forensic Medicine

Reference21 articles.

1. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.

2. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: A proposed classification of DNA histograms in breast cancer

3. The prognostic significance of ploidy analysis in operable breast cancer

4. DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer

5. The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stepwise increase of MIB-1 index in frequently relapsed malignant peritoneal mesothelioma;International Cancer Conference Journal;2017-03-07

2. Serum sFas and Tumor Tissue FasL Negatively Correlated with Survival in Egyptian Patients Suffering from Breast Ductal Carcinoma;Pathology & Oncology Research;2008-11-18

3. The Cancer and Leukemia Group B Pathology Committee at 50;Clinical Cancer Research;2006-06-01

4. L'évaluation conjointe du contenu en ADN et de la fraction de cellules en phase S est un paramètre pronostique indépendant dans les cancers du sein de stades I et II;Cancer/Radiothérapie;2005-12

5. Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients;Journal of Clinical Oncology;2005-07-01